Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Multi-Cancer Early Detection (MCED) Market Size, Share, Trends and Forecast 2026-2036 | Blood-Based Screening and AI Fuel 21.2% CAGR and $8.4 Billion Market by 2036

globenewswire.com
EXAS Exact Sciences Corporation is mentioned as a key company in the growing Multi-Cancer Early Detection (MCED) market. The article highlights the overall market growth driven by advances in diagnostics and AI, suggesting a positive outlook for companies like Exact Sciences. GH Guardant Health, Inc. is identified as a key player in the expanding Multi-Cancer Early Detection (MCED) market. The article's positive outlook on market growth, driven by technological advancements and increasing demand for early cancer detection, bodes well for Guardant Health. FGEN Freenome Holdings, Inc. is listed as a key company in the Multi-Cancer Early Detection (MCED) market, which is projected for significant growth. The article's focus on AI and blood-based screening as market drivers suggests a positive environment for Freenome. LH Laboratory Corporation of America Holdings (Labcorp) is mentioned as a key company in the MCED market. While the article is generally bullish on the MCED market, Labcorp's specific role or performance within this segment isn't detailed, leading to a neutral sentiment. TMO Thermo Fisher Scientific Inc. is listed as a key company in the MCED market. The article provides a positive outlook for the overall market, but does not offer specific details on Thermo Fisher's performance or strategic positioning within this segment, resulting in a neutral sentiment. BTAI Burning Rock Biotech Limited is identified as a key company in the rapidly expanding Multi-Cancer Early Detection (MCED) market. The article's positive outlook on market growth, driven by technological advancements and AI, suggests a favorable environment for the company. SGRX Singlera Genomics Inc. is named as a key participant in the growing Multi-Cancer Early Detection (MCED) market. The article's optimistic forecast for the MCED sector, fueled by AI and blood-based screening, indicates a positive outlook for Singlera Genomics. ILMN Illumina, Inc. is mentioned as a company within the MCED market landscape. While the article is bullish on the overall market, it doesn't provide specific details on Illumina's current performance or strategic focus within this niche, leading to a neutral sentiment. BIO Bio-Rad Laboratories, Inc. is mentioned as a company within the MCED market. The article's overall positive outlook on the MCED sector does not provide specific details on Bio-Rad's performance or strategic positioning, resulting in a neutral sentiment.

Global Multi-Cancer Early Detection (MCED) Market Size, Share, Trends and Forecast 2026-2036 | Blood-Based Screening and AI Fuel 21.2% CAGR and $8.4 Billion Market by 2036 Dublin, Nov. 05, 2026 (GLOBE NEWSWIRE) -- "Multi-Cancer Early Detection (MCED) Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.

The global Multi-Cancer Early Detection (MCED) Market was valued at USD 0.8 billion in 2025 and is projected to increase from an estimated USD 1.2 billion in 2026 to USD 8.4 billion by 2036, registering a CAGR of 21.2% during the forecast period. Market expansion is being driven by the rising global cancer burden, growing emphasis on early diagnosis, advances in molecular diagnostics, increasing adoption of precision oncology, and continued investment in blood-based cancer screening and biomarker discovery.

The report assesses market trends across technologies, cancer type coverage, sample types, products, applications, end users, and geographic regions. It also examines product innovation, clinical validation programs, regulatory developments, partnerships, investments, mergers and acquisitions, and competitive strategies shaping the global cancer diagnostics ecosystem.

Market Growth Drivers and Opportunities

Demand for MCED technologies is increasing as healthcare providers seek minimally invasive, accurate, and scalable solutions that can identify multiple cancer signals through a single testing workflow. Early-stage detection remains a major healthcare priority because it can expand treatment options and improve clinical outcomes. The limitations of conventional screening methods, particularly for cancers without established screening programs, are also supporting market growth.

Blood-based testing is expected to remain central to market development due to its minimally invasive collection process and ability to analyze circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), proteins, and other molecular signatures. These characteristics support the potential integration of MCED testing into population screening and high-risk population screening programs.

DNA methylation-based tests represent a significant technology segment because cancer-associated epigenetic alterations can support cancer signal detection and tissue of origin identification. Next-generation sequencing (NGS)-based tests are also gaining momentum by enabling simultaneous analysis of genomic abnormalities, mutations, and molecular patterns associated with multiple cancer types.

Multi-omics approaches offer additional growth opportunities by combining genomic, epigenomic, transcriptomic, proteomic, and metabolomic data. Alongside artificial intelligence-based analytics and advanced bioinformatics, these platforms may improve assay performance, cancer signal classification, and clinical interpretation.

Market development may be constrained by high testing costs, regulatory complexity, limited reimbursement, extensive clinical validation requirements, false-positive results, and the need for follow-up diagnostic procedures. Industry participants are responding through large-scale clinical trials, strategic collaborations, improved assay sensitivity, machine learning applications, and development of cost-effective testing platforms.

Segment Analysis

Regional Market Outlook

North America dominates the MCED market due to advanced healthcare infrastructure, strong cancer research investment, the presence of leading diagnostic companies, and extensive precision oncology activity. Europe represents another significant market, supported by government healthcare initiatives, molecular diagnostic capabilities, and a growing focus on early cancer diagnosis.

Asia-Pacific is expected to record strong growth as cancer incidence rises and healthcare infrastructure, biotechnology investment, and access to advanced diagnostics improve. China, Japan, India, South Korea, and Australia are key contributors to regional expansion. Latin America and the Middle East & Africa offer emerging opportunities associated with healthcare modernization, improved access to diagnostic services, and increasing awareness of cancer screening.

Competitive Landscape

Competition is centered on biomarker performance, clinical evidence, cancer detection coverage, tissue of origin identification, scalability, regulatory progress, data analytics, geographic reach, and commercialization readiness. Companies are expanding clinical validation studies, pursuing regulatory submissions, and forming partnerships with healthcare providers, academic institutions, pharmaceutical organizations, and government health programs.

Key companies profiled in the report include GRAIL, LLC, Exact Sciences Corporation, Guardant Health, Inc., Burning Rock Biotech Limited, Singlera Genomics Inc., Harbinger Health, Inc., Freenome Holdings, Inc., Naveris, Inc., Laboratory Corporation of America Holdings (Labcorp), and Thermo Fisher Scientific Inc.

Strategic Value of the Report

The report delivers actionable intelligence for diagnostic companies, pharmaceutical and biotechnology organizations, healthcare providers, government health programs, investors, and research institutions seeking to evaluate opportunities in the rapidly expanding global multi-cancer early detection market.

Key Topics Covered

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Market Ecosystem

1.4 Currency and Limitations

1.4.1 Currency

1.4.2 Limitations

1.5 Key Stakeholders

2. Research Methodology

2.1 Research Approach

2.2 Data Collection & Validation

2.2.1 Secondary Research

2.2.2 Primary Research (Oncologists, Diagnostics Firms, Labs, Pharma)

2.3 Market Estimation

2.3.1 Bottom-Up Approach

2.3.2 Top-Down Approach

2.3.3 Forecast Modeling

2.4 Data Triangulation

2.5 Assumptions

3. Executive Summary

4. Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Rising Global Cancer Burden

4.2.1.2 Need for Early Detection to Improve Survival Rates

4.2.1.3 Advancements in Genomics and Liquid Biopsy Technologies

4.2.1.4 Increasing Focus on Preventive Healthcare

4.2.2 Restraints

4.2.2.1 High Cost of MCED Tests

4.2.2.2 Limited Reimbursement Coverage

4.2.2.3 Clinical Validation and Regulatory Challenges

4.2.3 Opportunities

4.2.3.1 Expansion of Population-Level Screening Programs

4.2.3.2 Integration with AI and Multi-omics Analysis

4.2.3.3 Growth in Emerging Markets

4.2.3.4 Partnerships with Healthcare Systems

4.2.4 Challenges

4.2.4.1 False Positives/Negatives and Clinical Accuracy

4.2.4.2 Standardization of Screening Protocols

4.3 Technology Landscape

4.3.1 Next-Generation Sequencing (NGS)

4.3.2 DNA Methylation Analysis

4.3.3 Circulating Tumor DNA (ctDNA) Detection

4.3.4 Multi-omics (Genomics, Proteomics, Epigenomics)

4.3.5 AI and Machine Learning in Cancer Detection

4.4 MCED Ecosystem

4.4.1 Diagnostics & Genomics Companies

4.4.2 Pharmaceutical & Biotechnology Firms

4.4.3 Clinical Laboratories

4.4.4 Healthcare Providers

4.4.5 Research Institutes

4.5 Value Chain Analysis

4.5.1 Sample Collection

4.5.2 Sample Processing

4.5.3 Biomarker Detection

4.5.4 Data Analysis & Interpretation

4.5.5 Clinical Reporting

4.6 Regulatory Landscape

4.6.1 FDA & Global Regulatory Frameworks

4.6.2 Clinical Validation Requirements

4.6.3 Reimbursement Policies

4.7 Industry Trends

4.7.1 Rise of Population Screening Programs

4.7.2 Increasing Investment in Early Cancer Detection

4.7.3 Integration with Digital Health Platforms

4.7.4 Shift Toward Preventive Oncology

4.8 Cost and Pricing Analysis

4.8.1 Cost per Test Analysis

4.8.2 Pricing Trends by Region

4.8.3 Reimbursement Landscape

5. MCED Market, by Technology

5.1 Introduction

5.2 NGS-based MCED Tests

5.3 DNA Methylation-based Tests

5.4 Multi-omics Approaches

5.5 Other Technologies

6. MCED Market, by Cancer Type Coverage

6.1 Introduction

6.2 Pan-cancer Detection (Multiple Cancer Types)

6.3 Organ-specific Detection

6.3.1 Lung Cancer

6.3.2 Breast Cancer

6.3.3 Colorectal Cancer

6.3.4 Prostate Cancer

6.3.5 Liver Cancer

6.3.6 Other Cancers

7. MCED Market, by Sample Type

7.1 Blood (Plasma/Serum)

7.2 Urine

7.3 Saliva

7.4 Other Sample Types

8. MCED Market, by Product Type

8.1 Assays & Kits

8.2 Instruments

8.3 Software & Data Analytics Platforms

8.4 Services

9. MCED Market, by Application

9.1 Introduction

9.2 Population Screening

9.3 High-risk Population Screening

9.4 Early Diagnosis

9.5 Monitoring & Recurrence Detection

10. MCED Market, by End User

10.1 Hospitals & Clinics

10.2 Diagnostic Laboratories

10.3 Academic & Research Institutes

10.4 Government & Public Health Programs

11. MCED Market, by Geography

11.1 Introduction

11.2 North America

11.2.1 U.S.

11.2.2 Canada

11.3 Europe

11.3.1 Germany

11.3.2 U.K.

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 Netherlands

11.3.7 Sweden

11.3.8 Switzerland

11.3.9 Rest of Europe

11.4 Asia-Pacific

11.4.1 China

11.4.2 Japan

11.4.3 India

11.4.4 South Korea

11.4.5 Australia

11.4.6 Singapore

11.4.7 Rest of Asia-Pacific

11.5 Latin America

11.5.1 Brazil

11.5.2 Mexico

11.5.3 Rest of Latin America

11.6 Middle East & Africa

11.6.1 UAE

11.6.2 Saudi Arabia

11.6.3 South Africa

11.6.4 Rest of MEA

12. Competitive Landscape

12.1 Overview

12.2 Key Growth Strategies

12.3 Competitive Benchmarking

12.4 Competitive Dashboard

12.4.1 Industry Leaders

12.4.2 Market Differentiators

12.4.3 Emerging Players

12.5 Market Ranking/Positioning Analysis

13. Company Profiles

Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis

13.1 Grail, Inc.

13.2 Guardant Health, Inc.

13.3 Exact Sciences Corporation

13.4 Freenome Holdings, Inc.

13.5 Illumina, Inc.

13.6 Roche Diagnostics

13.7 Natera, Inc.

13.8 Burning Rock Biotech Ltd.

13.9 QIAGEN N.V.

13.10 Thermo Fisher Scientific Inc.

13.11 NeoGenomics Laboratories

13.12 Foundation Medicine (Roche)

13.13 Genetron Health

13.14 Singlera Genomics

13.15 Bio-Rad Laboratories, Inc.

14. Appendix

14.1 Customization Options

14.2 Related Reports

For more information about this report visit https://www.researchandmarkets.com/r/hjn06a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.